Skip to main content
padlock icon - secure page this page is secure

Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

Buy Article:

$52.00 + tax (Refund Policy)

P neumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer‐related immunosuppression. There are well‐defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment‐related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP. Trimethoprim‐sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Pneumocystis carinii; Pneumocystis jirovecii; haematological malignancy; prophylaxis; solid‐organ tumour; treatment

Document Type: Research Article

Publication date: December 1, 2014

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more